Home LiteratureArticle Details
PMID: 1890549 Published · ppublish English Journal Article

The vascularity of primary cutaneous melanoma.

The Journal of pathology ·Vol. 164 ·No. 3 ·1991-07-00 ·Pages 241-4

Fallowfield ME, Cook MG

Abstract

In primary cutaneous malignant melanoma, the vascularity of the dermis immediately deep to the lesion may relate to tumour aggressiveness and to prognosis. These newly formed dermal vessels are incorporated into the melanoma to form the tumour microcirculation. We have assessed the percentage vascular volume in a series of primary melanomas in order to investigate the relationship between tumour vascularity and maximum tumour thickness. For the 64 melanomas included in this study, there appeared to be a significant relationship between the percentage vascular volume and the maximum tumour thickness. This relationship was not influenced by the presence of necrosis, vascular invasion, regression, or lymphocytic infiltrate, nor by the growth phase of the tumour. However, the percentage vascular volume was very low in the occasional thick melanoma, at least one of which was associated with prolonged survival. It seems possible that a low tumour vascularity could correlate with a relatively favourable outcome in cutaneous melanoma.

MeSH Terms
Humans Melanoma/blood supply,pathology Microcirculation/pathology Skin/blood supply Skin Neoplasms/blood supply,pathology
Authors & Affiliations
2 authors, click to expand affiliations / ORCID
Fallowfield M E
Department of Histopathology, St George's Hospital Medical School, London, U.K.
Cook M G
Article Info
Journal
The Journal of pathology
Abbr.
J Pathol
ISSN
0022-3417
Published
1991-07-00
Pages
241-4
Language
English
Region
England
NLM ID
0204634
Subset
IM
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com